23andMe

Valuation $11B

About 23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Headquarters 23andMe, Sunnyvale
Founded 2006-04-01
Industry Biotechnology, Genetics, Life Science
Last Funding Type Post Ipo Equity
Valuation 11
Total Funding $1.12 billion dollars
IPO Status Public

Financial

23andMe is advancing in genetic analysis and ancestry determination. They are developing methods for analyzing genetic information between family members, finding relatives in databases, and determining identity-by-descent relatedness. Their research includes ancestry painting and ancestry composition determination, which involve displaying ancestral data and estimating parental contributions. They also focus on genetic-based recommendations and polygenic risk stratification for diseases like type 2 diabetes. These efforts highlight 23andMe's commitment to enhancing genetic insights and personalized health assessments.

Funding Rounds 14
Number of Lead Investors 7
Total Funding Amount  $1.12 billion dollars
Number of Investors 36

Related Angels

Martin Varsavsky
View profile
Anne Wojcicki
View profile
Esther Dyson
View profile